Preclinical assessment of fibroblast activation protein as a target for antitumor therapy

Future Oncology

Volumn 6, Issue 3, 2010, Pages 347-349

  Hayward, Simon W ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antitumor therapy; Fibroblast activation protein; Stromagenic response

Indexed keywords

ANTINEOPLASTIC AGENT; DIPEPTIDYL PEPTIDASE IV; FIBROBLAST ACTIVATION PROTEIN; K RAS PROTEIN; PEPTIDASE; PT 630; SERINE PROTEINASE; UNCLASSIFIED DRUG; VILDAGLIPTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CANCER INHIBITION; CLINICAL ASSESSMENT; COLON TUMOR; CONTROLLED STUDY; DRUG TARGETING; LUNG CANCER; MOUSE; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; TRANSGENIC MOUSE; TUMOR GROWTH; TUMOR XENOGRAFT;

EID: 77949429900     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.10.8     Document Type: Note

References (6)

1. Santos AM, Jung J, Aziz N, Kissil JL, Pure E: Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. J. Clin. Invest. 119(12), 3613-3625 (2009).
2. Martin MD, Matrisian LM: The other side of MMPs: protective roles in tumor progression. Cancer Metastasis Rev. 26(3-4), 717-724 (2007).
3. Henry LR, Lee HO, Lee JS et al. Clinical implications of fibroblast activation protein in patients with colon cancer. Clin. Cancer Res. 13(6), 1736-1741 (2007).
4. Cheng JD, Dunbrack RL Jr, Valianou M, Rogatko A, Alpaugh RK, Weiner LM: Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model. Cancer Res. 62(16), 4767-4772 (2002).
5. Scott AM, Wiseman G, Welt S et al.: A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin. Cancer Res. 9(5), 1639-1647 (2003).
6. Lebeau AM, Brennen WN, Aggarwal S, Denmeade SR: Targeting the cancer stroma with a fibroblast activation protein-activated promelittin protoxin. Mol. Cancer Ther. 8, 1378-1386 (2009).